Journal
CANCER TREATMENT REVIEWS
Volume 41, Issue 8, Pages 680-689Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.05.007
Keywords
Non-Hodgkin Lymphomas; Rituximab; Monoclonal antibodies; CD20; Apoptosis
Categories
Funding
- Fundacion Investigacion Biomedica Puerta de Hierro
- iPFIS fellowship from Institut de Salud Carlos III (ISCIII)-Fondos FEDER, Plan Estatal I+D+I [IFI14/00003]
- Miguel Servet Contract from ISCIII-Fondos FEDER, Plan Nacional I+D+I, Ministerio de Economia y Competitividad (MINECO) [CP11/00018]
Ask authors/readers for more resources
Anti-CD20 monoclonal antibodies (mAbs) have improved patient's survival with Non-Hodgkin Lymphoma, when combined with chemotherapy. Several mechanisms of action have been reported, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis. Despite the large amount of studies and published data, the role each mechanism played in vivo is not fully understood. Furthermore, the reason why a significant percentage of patients are refractory or resistant remains unknown. Several activated intracellular signaling pathways have been implicated in the mechanisms of resistance of rituximab. In the present manuscript, we review those mechanisms and new anti-CD20 mAbs, as well as the efforts being accomplished to overcome it, focusing on new drugs targeting pathways implicated in resistance to rituximab. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available